Subtype
Prostate Neoplasm
CI-CAN-00003778Explore in graph →
Non-malignant1,453 active trials24 approved drugs58 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003778Explore in graph →
Clinical trials
6,544 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06751524 | Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval | available | — | — | Agenus Inc.INDUSTRY | 0 | May 15, 2026 | clinicaltrials |
| NCT06836648 | Single Patient Compassionate Use of X-PACT in Salvage Treatment of Prostate Cancer | available | — | — | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 25, 2026 |
| clinicaltrials |
| NCT05974410 | Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients | available | — | — | AVM Biotechnology IncINDUSTRY | 0 | Oct 2, 2025 | clinicaltrials |
| NCT05650476 | Pre-approval Single-patient Expanded Access for Talazoparib (PF-06944076) | available | — | — | PfizerINDUSTRY | 0 | Jun 12, 2025 | clinicaltrials |
| NCT04337099 | A Single Patient Compassionate Use of MBM-02 (Tempol) for the Treatment of Prostate Cancer | available | — | — | Matrix Biomed, Inc.INDUSTRY | 1 | May 5, 2021 | clinicaltrials |
Data updated 22 days agoSource updated May 15, 2026source: clinicaltrials